We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Innovation Fuels Globus Medical's Growth Momentum
Read MoreHide Full Article
Key Takeaways
GMED launched new elbow, navigation, drill and AMS implant products to expand its portfolio.
GMED's R&D was 4.8% of Q1 2026 sales; full-year spending is expected at 5-6% of net sales.
Globus Medical gained FDA clearances for patient-specific lumbar spacers and rods in Q2.
Globus Medical (GMED - Free Report) continues to invest in research and development (R&D) and product cadence as a core part of its competitive positioning. Per the company, its team-oriented approach, active surgeon input and demonstrated capabilities position it to maintain a rapid rate of product launches.
In 2025, the company launched ANTHEM Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures. The company also launched DuraPro with Navigation, a next-generation, oscillating system designed to safeguard delicate tissue. In addition to DuraPro, it launched Verzera, a navigated high-speed drill system integrated with the ExcelsiusGPS and ExcelsiusHub system. In addition, Globus Medical expanded the Advanced Materials Science (“AMS”) implant portfolio with the COHERE ALIF Spacer.
In the first quarter of 2026, R&D expenses were 4.8% of sales, with management expecting it to be 5-6% of net sales for the full year, with spend ramping methodically through the year as product efforts progress.
The company’s early second-quarter FDA 510(k) clearances for patient-specific lumbar spacers and rods also reinforce its roadmap to link planning software, enabling technologies, and implants into a single workflow, which can deepen account relationships and increase procedure-level pull-through over time. This launch activity complements the broader post-merger strategy of compressing development timelines and keeping the portfolio fresh across spine and orthopedics.
Peer Update
Teleflex’s (TFX - Free Report) product development activity also remains robust. Recent additions include the AC3 range Intra-Aortic Balloon Pump, which received FDA 510(k) clearance in 2025 for patient transport use. Another addition is the Ringer Perfusion Balloon Catheter, which received FDA breakthrough device designation and is supported by an IDE study as it advances toward a coronary perforation indication. In emergency medicine, QuikClot Control+ gained FDA clearance for all grades of internal and external bleeding, expanding its potential use cases.
Thermo Fisher Scientific’s (TMO - Free Report) recent product launches include the PPD CorEvitas Chronic Hand Eczema Registry, a cohort registry designed to generate real-world evidence on patients being treated for chronic hand eczema in routine clinical care and Gibco CTS DynaXS Single Use Bioreactor, designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 34.2%, outperforming the industry’s 3.6% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month price-to-sales (P/S) of 3.31X compared with the industry median of 4.50X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Innovation Fuels Globus Medical's Growth Momentum
Key Takeaways
Globus Medical (GMED - Free Report) continues to invest in research and development (R&D) and product cadence as a core part of its competitive positioning. Per the company, its team-oriented approach, active surgeon input and demonstrated capabilities position it to maintain a rapid rate of product launches.
In 2025, the company launched ANTHEM Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures. The company also launched DuraPro with Navigation, a next-generation, oscillating system designed to safeguard delicate tissue. In addition to DuraPro, it launched Verzera, a navigated high-speed drill system integrated with the ExcelsiusGPS and ExcelsiusHub system. In addition, Globus Medical expanded the Advanced Materials Science (“AMS”) implant portfolio with the COHERE ALIF Spacer.
In the first quarter of 2026, R&D expenses were 4.8% of sales, with management expecting it to be 5-6% of net sales for the full year, with spend ramping methodically through the year as product efforts progress.
The company’s early second-quarter FDA 510(k) clearances for patient-specific lumbar spacers and rods also reinforce its roadmap to link planning software, enabling technologies, and implants into a single workflow, which can deepen account relationships and increase procedure-level pull-through over time. This launch activity complements the broader post-merger strategy of compressing development timelines and keeping the portfolio fresh across spine and orthopedics.
Peer Update
Teleflex’s (TFX - Free Report) product development activity also remains robust. Recent additions include the AC3 range Intra-Aortic Balloon Pump, which received FDA 510(k) clearance in 2025 for patient transport use. Another addition is the Ringer Perfusion Balloon Catheter, which received FDA breakthrough device designation and is supported by an IDE study as it advances toward a coronary perforation indication. In emergency medicine, QuikClot Control+ gained FDA clearance for all grades of internal and external bleeding, expanding its potential use cases.
Thermo Fisher Scientific’s (TMO - Free Report) recent product launches include the PPD CorEvitas Chronic Hand Eczema Registry, a cohort registry designed to generate real-world evidence on patients being treated for chronic hand eczema in routine clinical care and Gibco CTS DynaXS Single Use Bioreactor, designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 34.2%, outperforming the industry’s 3.6% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month price-to-sales (P/S) of 3.31X compared with the industry median of 4.50X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.